Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02268123 · ClinicalTrials.gov registry record
Correlating In Vitro Fertilization Outcomes After Euploid Blastocyst Transfer With Sperm DNA Fragmentation
A clinical trial, sponsored by Reproductive Medicine Associates of New Jersey.
- Completed
- Registry status
- 323
- Enrollment target
NCT02268123: Completed study, sponsored by Reproductive Medicine Associates of New Jersey.
NCT02268123 is a clinical trial that has completed, run by Reproductive Medicine Associates of New Jersey. The registered enrollment target is 323 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02268123 has completed, sponsored by Reproductive Medicine Associates of New Jersey.
- COMPLETED
- Registry status
- 323 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if sperm DNA fragmentation is associated with in vitro fertilization (IVF) outcomes when euploid embryos are transferred.
Primary Outcome
rates of fertilization, blastulation, implantation, sustained implantation, delivery and miscarriage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2014-10 |
| Est. Completion | 2018-07 |
What the finished NCT02268123 record still lists
NCT02268123 is an observational study that tracks outcomes without assigning an intervention. The registered 323 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02268123 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02268123 about?
NCT02268123 is a clinical study titled "Correlating In Vitro Fertilization Outcomes After Euploid Blastocyst Transfer With Sperm DNA Fragmentation". The purpose of this study is to determine if sperm DNA fragmentation is associated with in vitro fertilization (IVF) outcomes when euploid embryos are transferred.
What is the current status of trial NCT02268123?
This trial is currently completed. The enrollment target is 323 participants. The study started on 2014-10. Estimated completion is 2018-07.
Who is sponsoring clinical trial NCT02268123?
This trial is sponsored by Reproductive Medicine Associates of New Jersey, which has 51 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04164173 · 324 participants · NA
Hyperinflation Respiratory Therapies in Cardiac Surgery Patients
- NCT04708054 · 324 participants · Phase 2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- NCT05261399 · 324 participants · Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- NCT05353322 · 324 participants · NA
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia